Phase 2 Study of VX-970 (NSC# 780162) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs M 6620 (Primary) ; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2016 Status changed from not yet recruiting to recruiting.
- 29 Aug 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2019.